Moderna Therapeutics Inc., one of the best-funded private biotechnology companies in the U.S., unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy.
The Cambridge, Massachusetts-based startup has about $1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation Monday at the J.P.Morgan Chase & Co. Healthcare Conference in San Francisco. It’s privately valued at about $5 billion, according to a person familiar with the matter who asked not to be identified because the matter wasn’t public.
